These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32271694)

  • 1. Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis.
    Chen S; Liao Q; Lu K; Zhou J; Huang C; Bi F
    Curr Neurovasc Res; 2020; 17(3):275-285. PubMed ID: 32271694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole does not improve lifespan or motor function in three ALS mouse models.
    Hogg MC; Halang L; Woods I; Coughlan KS; Prehn JHM
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 Aug; 19(5-6):438-445. PubMed ID: 29221425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis.
    Wright AL; Della Gatta PA; Le S; Berning BA; Mehta P; Jacobs KR; Gul H; San Gil R; Hedl TJ; Riddell WR; Watson O; Keating SS; Venturato J; Chung RS; Atkin JD; Lee A; Shi B; Blizzard CA; Morsch M; Walker AK
    Eur J Neurosci; 2021 Sep; 54(6):6237-6255. PubMed ID: 34390052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A robust TDP-43 knock-in mouse model of ALS.
    Huang SL; Wu LS; Lee M; Chang CW; Cheng WC; Fang YS; Chen YR; Cheng PL; Shen CJ
    Acta Neuropathol Commun; 2020 Jan; 8(1):3. PubMed ID: 31964415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats.
    Huang C; Tong J; Bi F; Zhou H; Xia XG
    J Clin Invest; 2012 Jan; 122(1):107-18. PubMed ID: 22156203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness.
    Chen Q; Zhou J; Huang C; Huang B; Bi F; Zhou H; Xiao B
    Curr Neurovasc Res; 2018; 15(1):3-9. PubMed ID: 29313467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis.
    Dunlop J; Beal McIlvain H; She Y; Howland DS
    J Neurosci; 2003 Mar; 23(5):1688-96. PubMed ID: 12629173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene.
    Zhou H; Huang C; Chen H; Wang D; Landel CP; Xia PY; Bowser R; Liu YJ; Xia XG
    PLoS Genet; 2010 Mar; 6(3):e1000887. PubMed ID: 20361056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of ALS.
    Münch C; Ludolph AC
    Neurol Neurochir Pol; 2001; 35(1 Suppl):41-50. PubMed ID: 11732279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.
    Espejo-Porras F; Piscitelli F; Verde R; Ramos JA; Di Marzo V; de Lago E; Fernández-Ruiz J
    J Neuroimmune Pharmacol; 2015 Jun; 10(2):233-44. PubMed ID: 25819934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
    Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
    J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis.
    Wang DB; Gitcho MA; Kraemer BC; Klein RL
    Eur J Neurosci; 2011 Oct; 34(8):1179-88. PubMed ID: 21777407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of the CB
    Rodríguez-Cueto C; Gómez-Almería M; García Toscano L; Romero J; Hillard CJ; de Lago E; Fernández-Ruiz J
    Brain Pathol; 2021 Nov; 31(6):e12972. PubMed ID: 33983653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.
    Gurney ME; Fleck TJ; Himes CS; Hall ED
    Neurology; 1998 Jan; 50(1):62-6. PubMed ID: 9443458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of ALS and FTD: implications for translational studies.
    Liščić RM
    Arh Hig Rada Toksikol; 2015 Dec; 66(4):285-90. PubMed ID: 26751860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapies in amyotrophic lateral sclerosis-beyond riluzole.
    Morrison KE
    Curr Opin Pharmacol; 2002 Jun; 2(3):302-9. PubMed ID: 12020475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
    Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
    Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal over-expression of Oxr1 is protective against ALS-associated mutant TDP-43 mislocalisation in motor neurons and neuromuscular defects in vivo.
    Williamson MG; Finelli MJ; Sleigh JN; Reddington A; Gordon D; Talbot K; Davies KE; Oliver PL
    Hum Mol Genet; 2019 Nov; 28(21):3584-3599. PubMed ID: 31642482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.